ArticleFrontiers in microbiology2026
Protective effects of
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The present study aimed to evaluate the protective effects of Methods: A DSS-induced acute UC-like colitis mouse model was established to assess the effects of Br administration. Disease severity was evaluated based on body weight loss, disease activity index (DAI) scores, colon length, colon weight, intestinal barrier integrity, and histopathological changes using H&E staining. Inflammatory mediators, TLR4/TLR9 expression, tight junction (TJ) proteins, gut microbiota composition by 16S rRNA sequencing, and intestinal metabolic profiles by UPLC-MS/MS-based non-targeted metabolomics were also analyzed. Results: Br administration significantly ameliorated disease severity, as evidenced by mitigated body weight loss, reduced disease activity index (DAI) scores, attenuated colon shortening, normalized colon weight, and improved intestinal barrier integrity. Histopathological analysis (H&E) demonstrated that Br alleviated colonic tissue damage and inflammatory cell infiltration. The treatment also decreased the levels of proinflammatory mediators (IL-6, MPO, CXCL-1, and TNF-α) and downregulated the colonic expression of TLR4 and TLR9, while upregulating the expression of tight junction (TJ) proteins Occludin (OCC) and ZO-1. Furthermore, 16S rRNA sequencing revealed that Br restored gut microbial diversity and composition, specifically enriching potentially beneficial genera such as Discussion: Br water extract alleviates DSS-induced acute UC-like colitis injury in mice, possibly by attenuating inflammatory responses, downregulating abnormal TLR4/TLR9 expression, improving intestinal mucosal barrier function, and modulating gut microbiota composition and associated metabolic profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.